LLYD Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 5/6 |
Past Performance | 3/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Eli Lilly and Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$739.50 |
52 Week High | US$739.50 |
52 Week Low | US$389.80 |
Beta | 0.37 |
1 Month Change | 4.08% |
3 Month Change | 20.93% |
1 Year Change | 89.71% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 144.60% |
Recent News & Updates
Recent updates
Shareholder Returns
LLYD | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | 9.9% | 6.3% | 1.1% |
1Y | 89.7% | 5.7% | 1.9% |
Return vs Industry: LLYD exceeded the UK Pharmaceuticals industry which returned 5.4% over the past year.
Return vs Market: LLYD exceeded the UK Market which returned 2.3% over the past year.
Price Volatility
LLYD volatility | |
---|---|
LLYD Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 7.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.5% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: LLYD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LLYD's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
LLYD fundamental statistics | |
---|---|
Market cap | €654.14b |
Earnings (TTM) | €5.74b |
Revenue (TTM) | €33.61b |
113.9x
P/E Ratio19.5x
P/S RatioIs LLYD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LLYD income statement (TTM) | |
---|---|
Revenue | US$35.93b |
Cost of Revenue | US$7.13b |
Gross Profit | US$28.80b |
Other Expenses | US$22.66b |
Earnings | US$6.14b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
Earnings per share (EPS) | 6.82 |
Gross Margin | 80.16% |
Net Profit Margin | 17.08% |
Debt/Equity Ratio | 204.3% |
How did LLYD perform over the long term?
See historical performance and comparison